The RIVET RCT: Rifamycin SV MMX improves muscle mass, physical function, and ammonia in cirrhosis and minimal encephalopathy.

Saved in:
Bibliographic Details
Title: The RIVET RCT: Rifamycin SV MMX improves muscle mass, physical function, and ammonia in cirrhosis and minimal encephalopathy.
Authors: Bajaj JS; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA., Fagan A; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA., Gavis EA; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA., Mousel T; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA., Gallagher ML; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA., Puri P; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA., Fuchs M; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA., Davis BC; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA., Hylemon PB; Department of Microbiology and Immunology, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA., Zhou H; Department of Microbiology and Immunology, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA., Ahluwalia V; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA.; Center for Advanced Brain Imaging, Georgia Institute of Technology, Atlanta, Georgia, USA., Cadrain R; Collaborative Advanced Research Imaging Center, Virginia Commonwealth University, Richmond, Virginia, USA., Sikaroodi M; Microbiome Analysis Center, George Mason University, Manassas, Virginia, USA., Gillevet PM; Microbiome Analysis Center, George Mason University, Manassas, Virginia, USA.
Source: Hepatology communications [Hepatol Commun] 2024 Feb 03; Vol. 8 (2). Date of Electronic Publication: 2024 Feb 03 (Print Publication: 2024).
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 101695860 Publication Model: eCollection Cited Medium: Internet ISSN: 2471-254X (Electronic) Linking ISSN: 2471254X NLM ISO Abbreviation: Hepatol Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2471-254X
DOI:10.1097/HC9.0000000000000384